Paclitaxel/Hyaluronic acid

紫杉醇/透明质酸

Report date: 2025/07/17 10:41:50
NME

Base Information

Drug NamePaclitaxel/Hyaluronic acid
Drug Alias NameOncofid-PHA-paclitaxel bioconjugateHyaluronic acid-paclitaxelPaclitaxel-hyaluronic acidPaclitaxel-hyaluronic acid conjugate (Fidia pharma)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis inhibitorsCD44 antigen modulatorsTubulin inhibitors
TargetsCD44 antigenTubulin
Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Papillary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandItaly +[7] 
CombinationsYes PaclitaxelHyaluronic acid inhalation (Actelion Pharmaceuticals)
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesFidia Pharma
China Registration ClassN/A

Develop Information

Active CompaniesFidia Farmaceutici Spa
Inactive CompaniesN/A
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsCarcinoma, Papillary

Other Information

ATC CodeN/A
Related LinksN/A